Sujet(s)
Astrocytome , Tumeurs du cerveau , Glioblastome , Humains , Mâle , Tumeurs du cerveau/génétique , Tumeurs du cerveau/anatomopathologie , Tumeurs du cerveau/métabolisme , Tumeurs du cerveau/chirurgie , Adulte d'âge moyen , Astrocytome/génétique , Astrocytome/métabolisme , Astrocytome/anatomopathologie , Astrocytome/chirurgie , Glioblastome/anatomopathologie , Glioblastome/génétique , Glioblastome/chirurgie , Glioblastome/métabolisme , Phosphohydrolase PTEN/génétique , Phosphohydrolase PTEN/métabolisme , Mutation , Isocitrate dehydrogenases/génétique , Protéine gliofibrillaire acide/métabolisme , Protéine gliofibrillaire acide/génétique , Facteur de transcription-2 des oligodendrocytes/métabolismeRÉSUMÉ
PURPOSE: Post-operative MRI is used to assess extent of resection, monitor treatment response and detect progression in high-grade glioma. However, compliance with accepted guidelines for follow-up MRI, and impact on management/outcomes is unclear. METHODS: Multi-center, retrospective observational cohort study of patients with confirmed WHO grade 4 glioma (August 2018-February 2019) receiving oncological treatment. PRIMARY OBJECTIVE: investigate follow-up MRI surveillance practice and compliance with recommendations from NICE (Post-operative scan < 72h, MRI every 3-6 months) and EANO (Post-operative scan < 48h, MRI every 3 months). RESULTS: There were 754 patients from 26 neuro-oncology centers with a median age of 63 years (IQR 54-70), yielding 10,100 (median, 12.5/person, IQR 5.2-19.4) person-months of follow-up. Of patients receiving debulking surgery, most patients had post-operative MRI within 72 h of surgery (78.0%, N = 407/522), and within 48 h of surgery (64.2%, N = 335/522). The median number of subsequent follow-up MRI scans was 1 (IQR 0-4). Compliance with NICE and EANO recommendations for follow-up MRI was 52.8% (N = 398/754) and 24.9% (N = 188/754), respectively. On multivariable Cox regression analysis, increased time spent in recommended follow-up according to NICE guidelines was associated with longer OS (HR 0.56, 95% CI 0.46-0.66, P < 0.001), but not PFS (HR 0.93, 95% CI 0.79-1.10, P = 0.349). Increased time spent in recommended follow-up according to EANO guidelines was associated with longer OS (HR 0.54, 95% CI 0.45-0.63, P < 0.001) but not PFS (HR 0.99, 95% CI 0.84-1.16, P = 0.874). CONCLUSION: Regular surveillance follow-up for glioblastoma is associated with longer OS. Prospective trials are needed to determine whether regular or symptom-directed MRI influences outcomes.
Sujet(s)
Tumeurs du cerveau , Glioblastome , Imagerie par résonance magnétique , Humains , Adulte d'âge moyen , Femelle , Mâle , Tumeurs du cerveau/chirurgie , Tumeurs du cerveau/imagerie diagnostique , Tumeurs du cerveau/anatomopathologie , Sujet âgé , Glioblastome/chirurgie , Glioblastome/imagerie diagnostique , Glioblastome/anatomopathologie , Irlande , Études rétrospectives , Royaume-Uni , Études de suivi , Facteurs temps , Études de cohortes , Adhésion aux directives/statistiques et données numériquesRÉSUMÉ
Herein, we present two cases of isolated suprasellar dissemination of glioblastoma in patients with well-controlled primary lesions. A 22-year-old woman and a 56-year-old woman developed rapid growth of suprasellar glioblastoma dissemination 26 and 17 months after initial surgery, respectively. Both patients presented with acute visual impairment (decreased acuity and visual field disturbances) but lacked severe pituitary dysfunction. During surgery for the disseminated tumors, gross total tumor resection was difficult due to intraoperative findings suggesting optic pathway invasion. Both patients developed further intracranial dissemination within several months post-surgery. The presence of solitary sellar and suprasellar dissemination may indicate a terminal stage.
Sujet(s)
Glioblastome , Tumeurs de l'hypophyse , Selle turcique , Humains , Femelle , Glioblastome/chirurgie , Glioblastome/anatomopathologie , Glioblastome/imagerie diagnostique , Adulte d'âge moyen , Selle turcique/chirurgie , Selle turcique/anatomopathologie , Selle turcique/imagerie diagnostique , Jeune adulte , Tumeurs de l'hypophyse/chirurgie , Tumeurs de l'hypophyse/anatomopathologie , Tumeurs de l'hypophyse/imagerie diagnostique , Imagerie par résonance magnétique , Tumeurs du cerveau/chirurgie , Tumeurs du cerveau/anatomopathologie , Tumeurs du cerveau/imagerie diagnostique , Troubles de la vision/étiologie , Troubles de la vision/chirurgie , Invasion tumorale , Procédures de neurochirurgie/méthodesRÉSUMÉ
Background and Objectives: Notwithstanding the major progress in the management of cancerous diseases in the last few decades, glioblastoma (GBM) remains the most aggressive brain malignancy, with a dismal prognosis, mainly due to treatment resistance and tumoral recurrence. In order to diagnose this disease and establish the optimal therapeutic approach to it, a standard tissue biopsy or a liquid biopsy can be performed, although the latter is currently less common. To date, both tissue and liquid biopsy have yielded numerous biomarkers that predict the evolution and response to treatment in GBM. However, despite all such efforts, GBM has the shortest recorded survival rates of all the primary brain malignancies. Materials and Methods: We retrospectively reviewed patients with a confirmed histopathological diagnosis of glioblastoma between June 2011 and June 2023. All the patients were treated in the Third Neurosurgical Department of the Clinical Emergency Hospital "Bagdasar-Arseni" in Bucharest, and their outcomes were analyzed and presented accordingly. Results: Out of 518 patients in our study, 222 (42.8%) were women and 296 (57.14%) were men. The most common clinical manifestations were headaches and limb paralysis, while the most frequent tumor locations were the frontal and temporal lobes. The survival rates were prolonged in patients younger than 60 years of age, in patients with gross total tumoral resection and less than 30% tumoral necrosis, as well as in those who underwent adjuvant radiotherapy. Conclusions: Despite significant advancements in relation to cancer diseases, GBM is still a field of great interest for research and in great need of new therapeutic approaches. Although the multimodal therapeutic approach can improve the prognosis, the survival rates are still short and the recurrences are constant.
Sujet(s)
Tumeurs du cerveau , Glioblastome , Humains , Glioblastome/chirurgie , Glioblastome/mortalité , Glioblastome/thérapie , Études rétrospectives , Femelle , Mâle , Adulte d'âge moyen , Adulte , Sujet âgé , Tumeurs du cerveau/chirurgie , Tumeurs du cerveau/mortalité , Procédures de neurochirurgie/statistiques et données numériques , Procédures de neurochirurgie/méthodes , Résultat thérapeutique , Sujet âgé de 80 ans ou plus , Lituanie/épidémiologieRÉSUMÉ
PURPOSE: Patients with glioblastomas (GBMs) have poor prognosis despite various treatments; therefore, attention should be paid to maintaining the quality of survival. Neurocognitive deficits can affect the quality of life (QOL) in patients with GBM. Most studies concerning QOL and neurocognitive functions have demonstrated a relationship between QOL and self-reported neurocognitive decline, although this method does not accurately reflect damaged functional domains. Therefore, this study aimed to clarify the neurocognitive functions that influence the QOL in patients with GBMs using an objective assessment of neurocognitive functions. METHODS: Data from 40 patients newly diagnosed with GBMs were analyzed. All patients completed the assessment of QOL and various neurological and neurocognitive functions including general cognitive function, processing speed, attention, memory, emotion recognition, social cognition, visuospatial cognition, verbal fluency, language, motor function, sensation, and visual field at 6 months postoperatively. QOL was assessed using the 36-Item Short Form Survey (SF-36). In the SF-36, the physical, mental, and role and social component summary (PCS, MCS, and RCS, respectively) scores were calculated. Multiple logistic regression analyses and chi-square tests were used to evaluate the association between SF-36 scores and neurocognitive functions. RESULTS: The MCS was maintained, while the PCS and RCS scores were significantly lower in patients with GBMs than in healthy controls (p = 0.0040 and p < 0.0001, respectively). Among several neurocognitive functions, motor function and processing speed were significantly correlated with PCS and RCS scores, respectively (p = 0.0048 and p = 0.030, respectively). Patients who maintained their RCS or PCS scores had a higher probability of preserving motor function or processing speed than those with low RCS or PCS scores (p = 0.0026). CONCLUSIONS: Motor function and processing speed may be predictors of QOL in patients with GBMs.
Sujet(s)
Tumeurs du cerveau , Glioblastome , Qualité de vie , Humains , Qualité de vie/psychologie , Mâle , Femelle , Adulte d'âge moyen , Glioblastome/chirurgie , Glioblastome/psychologie , Tumeurs du cerveau/chirurgie , Tumeurs du cerveau/psychologie , Sujet âgé , Adulte , Tests neuropsychologiques/statistiques et données numériques , Cognition/physiologie , Vitesse de traitementRÉSUMÉ
Not all patients with glioblastoma multiforme (GBM) eligible for systemic chemotherapy after upfront surgery and radiotherapy finally receive it. The information on patients with GBM was retrieved from the surveillance, epidemiology, and end results database. Patients who underwent upfront surgery or biopsy and external beam radiotherapy between 2010 and 2019 were eligible for systemic chemotherapy. The available patient and tumor characteristics were assessed using multivariable logistic regression and chi-squared test. Out of the 16,682 patients eligible, 92.1% underwent systemic chemotherapy. The characteristics linked to the lowest systemic chemotherapy utilization included tumors of the brain stem/cerebellum (P = 0.01), former years of diagnosis (P = 0.001), ≥ 80 years of age (P < 0.001), Hispanic, Non-Hispanic Asian, Pacific Islander, or Black race (P < 0.001), non-partnered status (P < 0.001), and low median household income (P = 0.006). Primary tumor site, year of diagnosis, age, race, partnered status, and median household income correlated with the omission of systemic chemotherapy in GBM in adult patients.
Sujet(s)
Tumeurs du cerveau , Glioblastome , Humains , Glioblastome/thérapie , Glioblastome/chirurgie , Mâle , Femelle , Adulte d'âge moyen , Sujet âgé , Adulte , Tumeurs du cerveau/thérapie , Tumeurs du cerveau/épidémiologie , Facteurs socioéconomiques , Sujet âgé de 80 ans ou plus , Disparités d'accès aux soins , Programme SEERRÉSUMÉ
BACKGROUND: Glioblastoma patients may develop functional deficits post-operatively that affect activities of daily living and result in worse outcomes. The Activity Measure for Post-Acute Care (AM-PAC) instrument assigns patients basic mobility and daily activity scores, but it is unknown if these scores correlate with post-operative outcomes in glioblastoma patients. METHODS: Adult (≥18 years) glioblastoma patients evaluated by physical/occupational therapy after resection at a single instution (June 2008-December 2020) were identified. Patient demographics, post-operative AM-PAC scores, and clinical outcomes were collected. Multivariate regression identified associations between AM-PAC scores and post-operative outcomes. RESULTS: 600 patients were included (mean age 59.3 years, 59.2 % male); 151 (25.3 %) and 246 (43.8 %) patients had low mobility (<42.9) and activity (<39.4) scores, respectively. 103 (17.2 %) and 177 (29.5 %) patients experienced extended lengths of stay (LOS) in the ICU (≥2 days) and overall (≥7 days), respectively. 154 (25.7 %) patients had non-home discharges. The 30-day readmission rate was 13.7 %. In multivariate analysis, low mobility scores correlated with increased odds of extended overall (p < 0.0001) and ICU (p = 0.0004) LOS, non-home discharge (p < 0.0001), and 30-day readmission (p = 0.0405). Low activity scores correlated with extended overall LOS (<0.0001) and non-home discharge (p < 0.0001). In log-rank analysis, median survival time was shorter for patients with low mobility (9.5 vs. 14.7 months, p < 0.0001) and activity (10.6 vs. 16.3 months, p < 0.0001) scores than for high-scoring patients. CONCLUSION: AM-PAC basic mobility and daily activity scores are associated with outcomes after glioblastoma resection. These easily obtainable scores may be useful for prognosticating and guiding decision making in post-operative glioblastoma patients.
Sujet(s)
Activités de la vie quotidienne , Tumeurs du cerveau , Glioblastome , Humains , Glioblastome/chirurgie , Mâle , Adulte d'âge moyen , Femelle , Tumeurs du cerveau/chirurgie , Sujet âgé , Durée du séjour/statistiques et données numériques , Soins de suite/méthodes , Études rétrospectives , Adulte , Résultat thérapeutique , Complications postopératoires/épidémiologie , Complications postopératoires/diagnostic , Réadmission du patient/statistiques et données numériquesRÉSUMÉ
PURPOSE: Maximal-safe resection has been shown to improve overall survival in elderly patients with glioblastoma in observational studies, however, the only clinical trial comparing resection versus biopsy in elderly patients with surgically-accessible glioblastoma showed no improvements in overall survival. A meta-analysis is needed to assess whether surgical resection of glioblastoma in older patients improves surgical outcomes when compared to biopsy alone. METHODS: A search was conducted until October 9th, 2023, to identify published studies reporting the clinical outcomes of glioblastoma patients > 65 years undergoing resection or biopsy (PubMed, MEDLINE, EMBASE, and COCHRANE). Primary outcomes were overall survival (OS), progression-free survival (PFS), and complications. We analyzed mean difference (MD) and hazard ratio (HR) for survival outcomes. Postoperative complications were analyzed as a dichotomic categorical variable with risk ratio (RR). RESULTS: From 784 articles, 20 cohort studies and 1 randomized controlled trial met our inclusion criteria, considering 20,523 patients for analysis. Patients undergoing surgical resection had an overall survival MD of 6.13 months (CI 95%=2.43-9.82, p = < 0.001) with a HR of 0.43 (95% CI = 0.35-0.52, p = < 0.00001). The progression-free survival MD was 2.34 months (95%CI = 0.79-3.89, p = 0.003) with a 0.50 h favoring resection (95%CI = 0.37-0.68, p = < 0.00001). The complication RR was higher in the resection group favoring biopsy (1.49, 95%CI = 1.06-2.10). CONCLUSIONS: Our meta-analysis suggests that upfront resection is associated with improved overall survival and progression-free survival in elderly patients with newly diagnosed glioblastoma over biopsy. However, postoperative complications are more common with resection. Future clinical trials are essential to provide more robust evaluation in this challenging patient population.
Sujet(s)
Tumeurs du cerveau , Glioblastome , Procédures de neurochirurgie , Humains , Glioblastome/chirurgie , Glioblastome/anatomopathologie , Glioblastome/mortalité , Tumeurs du cerveau/chirurgie , Tumeurs du cerveau/anatomopathologie , Tumeurs du cerveau/mortalité , Pronostic , Sujet âgé , Biopsie , Procédures de neurochirurgie/méthodesRÉSUMÉ
PURPOSE: PreOperative radiotherapy (RT) is commonly used in the treatment of brain metastasis and different cancer types but has never been used in primary glioblastoma (GBM). Here, we aim to establish, describe, and validate the use of PreOperative RT for the treatment of GBM in a preclinical model. METHODS: Rat brains were locally irradiated with 30-Gy, hypofractionated in five doses 2 weeks before or after the resection of intracranial GBM. Kaplan-Meier analysis determined survival. Hematoxylin-eosin staining was performed, and nuclei size and p21 senescence marker were measured in both resected and recurrent rodent tumors. Immunohistochemistry assessed microglia/macrophage markers, and RNAseq analyzed gene expression changes in recurrent tumors. Akoya Multiplex Staining on two human patients from our ongoing Phase I/IIa trial served as proof of principle. RESULTS: PreOperative RT group median survival was significantly higher than PostOperative RT (p < 0.05). Radiation enlarged cytoplasm and nuclei in PreOperative RT resected tumors (p < 0.001) and induced senescence in PostOperative RT recurrent tumors (p < 0.05). Gene Set Enrichment Analysis (GSEA) suggested a more proliferative profile in PreOperative RT group. PreOperative RT showed lower macrophage/microglia recruitment in recurrent tumors (p < 0.01) compared to PostOperative RT. Akoya Multiplex results indicated TGF-ß accumulation in the cytoplasm of TAMs and CD4 + lymphocyte predominance in PostOperative group. CONCLUSIONS: This is the first preclinical study showing feasibility and longer overall survival using neoadjuvant radiotherapy before GBM resection in a mammalian model. This suggests strong superiority for new clinical radiation strategies. Further studies and trials are required to confirm our results.
Sujet(s)
Tumeurs du cerveau , Glioblastome , Glioblastome/radiothérapie , Glioblastome/anatomopathologie , Glioblastome/métabolisme , Glioblastome/chirurgie , Animaux , Tumeurs du cerveau/radiothérapie , Tumeurs du cerveau/anatomopathologie , Tumeurs du cerveau/métabolisme , Tumeurs du cerveau/chirurgie , Humains , Rats , Modèles animaux de maladie humaine , Mâle , Récidive tumorale locale/anatomopathologie , Soins préopératoires , FemelleRÉSUMÉ
BACKGROUND: Quantifying tumor growth and treatment response noninvasively poses a challenge to all experimental tumor models. The aim of our study was, to assess the value of quantitative and visual examination and radiomic feature analysis of high-resolution MR images of heterotopic glioblastoma xenografts in mice to determine tumor cell proliferation (TCP). METHODS: Human glioblastoma cells were injected subcutaneously into both flanks of immunodeficient mice and followed up on a 3 T MR scanner. Volumes and signal intensities were calculated. Visual assessment of the internal tumor structure was based on a scoring system. Radiomic feature analysis was performed using MaZda software. The results were correlated with histopathology and immunochemistry. RESULTS: 21 tumors in 14 animals were analyzed. The volumes of xenografts with high TCP (H-TCP) increased, whereas those with low TCP (L-TCP) or no TCP (N-TCP) continued to decrease over time (p < 0.05). A low intensity rim (rim sign) on unenhanced T1-weighted images provided the highest diagnostic accuracy at visual analysis for assessing H-TCP (p < 0.05). Applying radiomic feature analysis, wavelet transform parameters were best for distinguishing between H-TCP and L-TCP / N-TCP (p < 0.05). CONCLUSION: Visual and radiomic feature analysis of the internal structure of heterotopically implanted glioblastomas provide reproducible and quantifiable results to predict the success of transplantation.
Sujet(s)
Tumeurs du cerveau , Glioblastome , Imagerie par résonance magnétique , Transplantation tumorale , Animaux , Femelle , Humains , Mâle , Souris , Tumeurs du cerveau/imagerie diagnostique , Tumeurs du cerveau/chirurgie , Tumeurs du cerveau/anatomopathologie , Lignée cellulaire tumorale , Prolifération cellulaire , Modèles animaux de maladie humaine , Glioblastome/imagerie diagnostique , Glioblastome/chirurgie , Glioblastome/anatomopathologie , Traitement d'image par ordinateur , Imagerie par résonance magnétique/méthodes , Transplantation tumorale/méthodes ,RÉSUMÉ
BACKGROUND: Surgery is crucial for glioma treatment, but achieving complete tumour removal remains challenging. We evaluated the effectiveness of a probe targeting monocarboxylate transporter 4 (MCT4) in recognising gliomas, and of near-infrared window II (NIR-II) fluorescent molecular imaging and photothermal therapy as treatment strategies. METHODS: We combined an MCT4-specific monoclonal antibody with indocyanine green to create the probe. An orthotopic mouse model and a transwell model were used to evaluate its ability to guide tumour resection using NIR-II fluorescence and to penetrate the blood-brain barrier (BBB), respectively. A subcutaneous tumour model was established to confirm photothermal therapy efficacy. Probe specificity was assessed in brain tissue from mice and humans. Finally, probe effectiveness in photothermal therapy was investigated. FINDINGS: MCT4 was differentially expressed in tumour and normal brain tissue. The designed probe exhibited precise tumour targeting. Tumour imaging was precise, with a signal-to-background (SBR) ratio of 2.8. Residual tumour cells were absent from brain tissue postoperatively (SBR: 6.3). The probe exhibited robust penetration of the BBB. Moreover, the probe increased the tumour temperature to 50 °C within 5 min of laser excitation. Photothermal therapy significantly reduced tumour volume and extended survival time in mice without damage to vital organs. INTERPRETATION: These findings highlight the potential efficacy of our probe for fluorescence-guided surgery and therapeutic interventions. FUNDING: Jilin Province Department of Science and Technology (20200403079SF), Department of Finance (2021SCZ06) and Development and Reform Commission (20200601002JC); National Natural Science Foundation of China (92059207, 92359301, 62027901, 81930053, 81227901, U21A20386); and CAS Youth Interdisciplinary Team (JCTD-2021-08).
Sujet(s)
Tumeurs du cerveau , Glioblastome , Transporteurs d'acides monocarboxyliques , Thérapie photothermique , Animaux , Souris , Transporteurs d'acides monocarboxyliques/métabolisme , Transporteurs d'acides monocarboxyliques/antagonistes et inhibiteurs , Humains , Thérapie photothermique/méthodes , Glioblastome/thérapie , Glioblastome/métabolisme , Glioblastome/imagerie diagnostique , Glioblastome/anatomopathologie , Glioblastome/chirurgie , Lignée cellulaire tumorale , Tumeurs du cerveau/thérapie , Tumeurs du cerveau/métabolisme , Tumeurs du cerveau/imagerie diagnostique , Tumeurs du cerveau/anatomopathologie , Tumeurs du cerveau/chirurgie , Chirurgie assistée par ordinateur/méthodes , Modèles animaux de maladie humaine , Barrière hémato-encéphalique/métabolisme , Protéines du muscle/métabolisme , Imagerie optique/méthodes , Tests d'activité antitumorale sur modèle de xénogreffeRÉSUMÉ
OBJECTIVE: Patients with glioblastoma (GBM) often undergo surgery to prolong survival. However, the use of surgery, and more specifically achieving gross total resection (GTR), in patients >80 years old has yet to be fully assessed. Using the Surveillance, Epidemiology, and End Results (SEER) database, we aim to assess the efficacy of surgical resection, radiotherapy (RT) and chemotherapy (CT) on overall survival (OS) in very elderly GBM patients compared to elderly counterparts (age 65-79 years). METHODS: The SEER database was queried for all patients >65 years old with GBM (2000-2020). Patients not undergoing surgery or biopsy were excluded. Patients were stratified by age, and demographic relationships were assessed with chi-squared testing for categorical variables. Bivariable models were created using Kaplan-Meier survival estimates. All significant variables from bivariable analysis were included on multivariable Cox survival regression models to determine independent associations between clinical variables and OS. RESULTS: A total of 27,090 operative GBM patients were identified; 1868 patients (15.92â¯%) were very elderly and 10,092 patients (84.38â¯%) were elderly. Very elderly patients were less likely to undergo GTR (28â¯% vs 35â¯%, p<0.001), RT (59â¯% vs 78â¯%, p<0.001) and CT (40â¯% vs 66â¯%, p<0.001). In multivariable Cox regression analysis, very elderly patients who achieved GTR (HR=.696, p<0.001), received RT (HR=0.583, p<0.001) and underwent CT (HR=0.4197, p<0.001) had significantly improved OS compared to very elderly patients that did not undergo these treatment options. CONCLUSION: Currently, very elderly GBM patients undergo lower rates of aggressive surgery, RT and CT. However, very elderly patients that undergo surgery, RT and CT may have a survival advantage. These treatments should be considered as potential options for this patient population.
Sujet(s)
Tumeurs du cerveau , Glioblastome , Procédures de neurochirurgie , Programme SEER , Humains , Glioblastome/chirurgie , Glioblastome/mortalité , Glioblastome/thérapie , Sujet âgé , Tumeurs du cerveau/chirurgie , Tumeurs du cerveau/mortalité , Mâle , Sujet âgé de 80 ans ou plus , Femelle , Résultat thérapeutique , Facteurs âgesRÉSUMÉ
5-Aminolevulinic Acid (5-ALA) is the only fluorophore approved by the FDA as an intraoperative optical imaging agent for fluorescence-guided surgery in patients with glioblastoma. The dosing regimen is based on rodent tests where a maximum signal occurs around 6 h after drug administration. Here, we construct a computational framework to simulate the transport of 5-ALA through the stomach, blood, and brain, and the subsequent conversion to the fluorescent agent protoporphyrin IX at the tumor site. The framework combines compartmental models with spatially-resolved partial differential equations, enabling one to address questions regarding quantity and timing of 5-ALA administration before surgery. Numerical tests in two spatial dimensions indicate that, for tumors exceeding the detection threshold, the time to peak fluorescent concentration is 2-7 h, broadly consistent with the current surgical guidelines. Moreover, the framework enables one to examine the specific effects of tumor size and location on the required dose and timing of 5-ALA administration before glioblastoma surgery.
Sujet(s)
Acide amino-lévulinique , Tumeurs du cerveau , Simulation numérique , Glioblastome , Concepts mathématiques , Modèles biologiques , Protoporphyrines , Chirurgie assistée par ordinateur , Glioblastome/chirurgie , Glioblastome/traitement médicamenteux , Glioblastome/anatomopathologie , Glioblastome/imagerie diagnostique , Acide amino-lévulinique/administration et posologie , Humains , Tumeurs du cerveau/chirurgie , Protoporphyrines/administration et posologie , Protoporphyrines/métabolisme , Chirurgie assistée par ordinateur/méthodes , Animaux , Photosensibilisants/administration et posologie , Imagerie optique/méthodes , Colorants fluorescents/administration et posologieRÉSUMÉ
PURPOSE: The presurgical discrimination of IDH-mutant astrocytoma grade 4 from IDH-wildtype glioblastoma is crucial for patient management, especially in younger adults, aiding in prognostic assessment, guiding molecular diagnostics and surgical planning, and identifying candidates for IDH-targeted trials. Despite its potential, the full capabilities of DSC-PWI remain underexplored. This research evaluates the differentiation ability of relative-cerebral-blood-volume (rCBV) percentile values for the enhancing and non-enhancing tumor regions compared to the more commonly used mean or maximum preselected rCBV values. METHODS: This retrospective study, spanning 2016-2023, included patients under 55 years (age threshold based on World Health Organization recommendations) with grade 4 astrocytic tumors and known IDH status, who underwent presurgical MR with DSC-PWI. Enhancing and non-enhancing regions were 3D-segmented to calculate voxel-level rCBV, deriving mean, maximum, and percentile values. Statistical analyses were conducted using the Mann-Whitney U test and AUC-ROC. RESULTS: The cohort consisted of 59 patients (mean age 46; 34 male): 11 astrocytoma-4 and 48 glioblastoma. While glioblastoma showed higher rCBV in enhancing regions, the differences were not significant. However, non-enhancing astrocytoma-4 regions displayed notably higher rCBV, particularly in lower percentiles. The 30th rCBV percentile for non-enhancing regions was 0.705 in astrocytoma-4, compared to 0.458 in glioblastoma (p = 0.001, AUC-ROC = 0.811), outperforming standard mean and maximum values. CONCLUSION: Employing an automated percentile-based approach for rCBV selection enhances differentiation capabilities, with non-enhancing regions providing more insightful data. Elevated rCBV in lower percentiles of non-enhancing astrocytoma-4 is the most distinguishable characteristic and may indicate lowly vascularized infiltrated edema, contrasting with glioblastoma's pure edema.
Sujet(s)
Astrocytome , Tumeurs du cerveau , Glioblastome , Humains , Glioblastome/imagerie diagnostique , Glioblastome/anatomopathologie , Glioblastome/chirurgie , Mâle , Astrocytome/imagerie diagnostique , Astrocytome/chirurgie , Astrocytome/anatomopathologie , Tumeurs du cerveau/imagerie diagnostique , Tumeurs du cerveau/anatomopathologie , Tumeurs du cerveau/chirurgie , Femelle , Adulte d'âge moyen , Études rétrospectives , Adulte , Grading des tumeurs , Diagnostic différentiel , Imagerie par résonance magnétique/méthodes , Volume sanguin cérébral , Soins préopératoires/méthodesRÉSUMÉ
BACKGROUND AND OBJECTIVES: Contrast enhancement in glioblastoma, IDH-wildtype is common but not systematic. In the era of the WHO 2021 Classification of CNS Tumors, the prognostic impact of a contrast enhancement and the pattern of contrast enhancement is not clearly elucidated. METHODS: We performed an observational, retrospective, single-centre cohort study at a tertiary neurosurgical oncology centre (January 2006 - December 2022). We screened adult patients with a newly-diagnosed glioblastoma, IDH-wildtype in order to assess the prognosis role of the contrast enhancement and the pattern of contrast enhancement. RESULTS: We included 1149 glioblastomas, IDH-wildtype: 26 (2.3%) had a no contrast enhancement, 45 (4.0%) had a faint and patchy contrast enhancement, 118 (10.5%) had a nodular contrast enhancement, and 960 (85.5%) had a ring-like contrast enhancement. Overall survival was longer in non-contrast enhanced glioblastomas (26.7 months) than in contrast enhanced glioblastomas (10.9 months) (p < 0.001). In contrast enhanced glioblastomas, a ring-like pattern was associated with shorter overall survival than in faint and patchy and nodular patterns (10.0 months versus 13.0 months, respectively) (p = 0.033). Whatever the presence of a contrast enhancement and the pattern of contrast enhancement, surgical resection was an independent predictor of longer overall survival, while age ≥ 70 years, preoperative KPS score < 70, tumour volume ≥ 30cm3, and postoperative residual contrast enhancement were independent predictors of shorter overall survival. CONCLUSION: A contrast enhancement is present in the majority (97.7%) of glioblastomas, IDH-wildtype and, regardless of the pattern, is associated with a shorter overall survival. The ring-like pattern of contrast enhancement is typical in glioblastomas, IDH-wildtype (85.5%) and remains an independent predictor of shorter overall survival compared to other patterns (faint and patchy and nodular).
Sujet(s)
Tumeurs du cerveau , Produits de contraste , Glioblastome , Isocitrate dehydrogenases , Imagerie par résonance magnétique , Humains , Glioblastome/imagerie diagnostique , Glioblastome/anatomopathologie , Glioblastome/mortalité , Glioblastome/chirurgie , Mâle , Femelle , Études rétrospectives , Adulte d'âge moyen , Tumeurs du cerveau/imagerie diagnostique , Tumeurs du cerveau/mortalité , Tumeurs du cerveau/anatomopathologie , Tumeurs du cerveau/chirurgie , Imagerie par résonance magnétique/méthodes , Pronostic , Isocitrate dehydrogenases/génétique , Sujet âgé , Adulte , Organisation mondiale de la santéRÉSUMÉ
The aim of this case study was to describe differences in English and British Sign Language (BSL) communication caused by a left temporal tumour resulting in discordant presentation of symptoms, intraoperative stimulation mapping during awake craniotomy and post-operative language abilities. We report the first case of a hearing child of deaf adults, who acquired BSL with English as a second language. The patient presented with English word finding difficulty, phonemic paraphasias, and reading and writing challenges, with BSL preserved. Intraoperatively, object naming and semantic fluency tasks were performed in English and BSL, revealing differential language maps for each modality. Post-operative assessment confirmed mild dysphasia for English with BSL preserved. These findings suggest that in hearing people who acquire a signed language as a first language, topographical organisation may differ to that of a second, spoken, language.
Sujet(s)
Tumeurs du cerveau , Craniotomie , Glioblastome , Langue des signes , Lobe temporal , Humains , Glioblastome/chirurgie , Craniotomie/méthodes , Tumeurs du cerveau/chirurgie , Tumeurs du cerveau/complications , Tumeurs du cerveau/imagerie diagnostique , Lobe temporal/chirurgie , Lobe temporal/imagerie diagnostique , Cartographie cérébrale/méthodes , Mâle , Vigilance/physiologie , Parole/physiologie , Multilinguisme , Langage , AdulteRÉSUMÉ
BACKGROUND: This study investigated the factors influencing short-term survivors (STS) after gross total resection (GTR) in patients with IDH1 wild-type primary glioblastoma. METHODS: We analyzed five independent cohorts who underwent GTR, including 83 patients from Kitasato University (K-cohort), and four validation cohorts of 148 patients from co-investigators (V-cohort), 66 patients from the Kansai Molecular Diagnosis Network for the Central Nervous System tumors, 109 patients from the Cancer Genome Atlas, and 40 patients from the Glioma Longitudinal AnalySiS. The study defined STS as those who had an overall survival ≤ 12 months after GTR with subsequent radiation therapy, and concurrent and adjuvant temozolomide (TMZ). RESULTS: The study included 446 patients with glioblastoma. All cohorts experienced unexpected STS after GTR, with a range of 15.0-23.9% of the cases. Molecular profiling revealed no significant difference in major genetic alterations between the STS and non-STS groups, including MGMT, TERT, EGFR, PTEN, and CDKN2A. Clinically, the STS group had a higher incidence of non-local recurrence early in their treatment course, with 60.0% of non-local recurrence in the K-cohort and 43.5% in the V-cohort. CONCLUSIONS: The study revealed that unexpected STS after GTR in patients with glioblastoma is not uncommon and such tumors tend to present early non-local recurrence. Interestingly, we did not find any significant genetic alterations in the STS group, indicating that such major alterations are characteristics of GB rather than being reliable predictors for recurrence patterns or development of unexpected STS.
Sujet(s)
Tumeurs du cerveau , Glioblastome , Isocitrate dehydrogenases , Humains , Glioblastome/génétique , Glioblastome/mortalité , Glioblastome/chirurgie , Glioblastome/thérapie , Glioblastome/anatomopathologie , Isocitrate dehydrogenases/génétique , Mâle , Tumeurs du cerveau/génétique , Tumeurs du cerveau/mortalité , Tumeurs du cerveau/chirurgie , Tumeurs du cerveau/thérapie , Tumeurs du cerveau/anatomopathologie , Femelle , Adulte d'âge moyen , Sujet âgé , Adulte , Procédures de neurochirurgie , Études de cohortes , Jeune adulte , Taux de survieRÉSUMÉ
PURPOSE: GammaTile® (GT) is a brachytherapy platform that received Federal Drug Administration (FDA) approval as brain tumor therapy in late 2018. Here, we reviewed our institutional experience with GT as treatment for recurrent glioblastomas and characterized dosimetric parameter and associated clinical outcome. METHODS AND MATERIALS: A total of 20 consecutive patients with 21 (n = 21) diagnosis of recurrent glioblastoma underwent resection followed by intraoperative GT implant between 01/2019 and 12/2020. Data on gross tumor volume (GTV), number of GT units implanted, dose coverage for the high-risk clinical target volume (HR-CTV), measured by D90 or dose received by 90% of the HR-CTV, dose to organs at risk, and six months local control were collected. RESULTS: The median D90 to HR-CTV was 56.0 Gy (31.7-98.7 Gy). The brainstem, optic chiasm, ipsilateral optic nerve, and ipsilateral hippocampus median Dmax were 11.2, 5.4, 6.4, and 10.0 Gy, respectively. None of the patients in this study cohort suffered from radiation necrosis or adverse events attributable to the GT. Correlation was found between pre-op GTV, the volume of the resection cavity, and the number of GT units implanted. Of the resection cavities, 7/21 (33%) of the cavity experienced shrinkage, 3/21 (14%) remained stable, and 11/21 (52%) of the cavities expanded on the 3-months post-resection/GT implant MRIs. D90 to HR-CTV was found to be associated with local recurrence at 6-month post GT implant, suggesting a dose response relationship (p = 0.026). The median local recurrence-free survival was 366.5 days (64-1,098 days), and a trend towards improved local recurrence-free survival was seen in patients with D90 to HR-CTV ≥ 56 Gy (p = 0.048). CONCLUSIONS: Our pilot, institutional experience provides clinical outcome, dosimetric considerations, and offer technical guidance in the clinical implementation of GT brachytherapy.
Sujet(s)
Curiethérapie , Tumeurs du cerveau , Glioblastome , Dosimétrie en radiothérapie , Planification de radiothérapie assistée par ordinateur , Humains , Tumeurs du cerveau/radiothérapie , Tumeurs du cerveau/chirurgie , Mâle , Femelle , Adulte d'âge moyen , Curiethérapie/méthodes , Sujet âgé , Projets pilotes , Planification de radiothérapie assistée par ordinateur/méthodes , Glioblastome/radiothérapie , Glioblastome/chirurgie , Glioblastome/imagerie diagnostique , Adulte , Récidive tumorale locale/radiothérapie , Récidive tumorale locale/anatomopathologie , Études rétrospectives , Études de suivi , Radiométrie , Organes à risque/effets des radiations , PronosticRÉSUMÉ
Safe and effective brain tumor surgery aims to remove tumor tissue, not non-tumoral brain. This is a challenge since tumor cells are often not visually distinguishable from peritumoral brain during surgery. To address this, we conducted a multicenter study testing whether the Sentry System could distinguish the three most common types of brain tumors from brain tissue in a label-free manner. The Sentry System is a new real time, in situ brain tumor detection device that merges Raman spectroscopy with machine learning tissue classifiers. Nine hundred and seventy-six in situ spectroscopy measurements and colocalized tissue specimens were acquired from 67 patients undergoing surgery for glioblastoma, brain metastases, or meningioma to assess tumor classification. The device achieved diagnostic accuracies of 91% for glioblastoma, 97% for brain metastases, and 96% for meningiomas. These data show that the Sentry System discriminated tumor containing tissue from non-tumoral brain in real time and prior to resection.
Sujet(s)
Tumeurs du cerveau , Analyse spectrale Raman , Humains , Tumeurs du cerveau/diagnostic , Tumeurs du cerveau/anatomopathologie , Tumeurs du cerveau/chirurgie , Analyse spectrale Raman/méthodes , Mâle , Femelle , Adulte d'âge moyen , Sujet âgé , Méningiome/diagnostic , Méningiome/anatomopathologie , Glioblastome/anatomopathologie , Glioblastome/diagnostic , Glioblastome/chirurgie , Adulte , Apprentissage machine , Encéphale/anatomopathologie , Encéphale/imagerie diagnostiqueRÉSUMÉ
BACKGROUND: This study aims to investigate the benefits of employing a Physical Lifelike Brain (PLB) simulator for training medical students in performing craniotomy for glioblastoma removal and decompressive craniectomy. METHODS: This prospective study included 30 medical clerks (fifth and sixth years in medical school) at a medical university. Before participating in the innovative lesson, all students had completed a standard gross anatomy course as part of their curriculum. The innovative lesson involved PLB Simulator training, after which participants completed the Learning Satisfaction/Confidence Perception Questionnaire and some received qualitative interviews. RESULTS: The average score of students' overall satisfaction with the innovative lesson was 4.71 out of a maximum of 5 (SD = 0.34). After the lesson, students' confidence perception level improved significantly (t = 9.38, p < 0.001, effect size = 1.48), and the average score improved from 2,15 (SD = 1.02) to 3.59 (SD = 0.93). 60% of the students thought that the innovative lesson extremely helped them understand the knowledge of surgical neuroanatomy more, 70% believed it extremely helped them improve their skills in burr hole, and 63% thought it was extremely helpful in improving the patient complications of craniotomy with the removal of glioblastoma and decompressive craniectomy after completing the gross anatomy course. CONCLUSION: This innovative lesson with the PLB simulator successfully improved students' craniotomy knowledge and skills.